Thyrocare Q4FY26 PAT Jumps 128% YoY to ₹48.7 Cr on 20% Revenue Growth
Thyrocare reported a 128% YoY jump in consolidated PAT to ₹48.70 crore for Q4FY26, on 20% revenue growth to ₹223.95 crore. FY26 consolidated PAT grew 81% YoY to ₹162.85 crore. Standalone PAT surged 101% YoY to ₹43.58 crore in Q4FY26. Active franchisees increased 15% YoY to ~10,800.
The substantial increase in PAT and revenue, coupled with positive operational metrics and a clear forward-looking strategy, is likely to have a significant positive impact on investor sentiment and the company's stock performance.
The company reported significant year-on-year growth in revenue, EBITDA, and particularly in Profit After Tax for both the quarter and the full financial year, indicating strong financial performance.
Thyrocare Technologies Limited announced its audited financial results for the quarter and financial year ended March 31, 2026. The company reported a consolidated revenue of ₹223.95 crore for Q4FY26, a 20% increase year-on-year (YoY). Reported EBITDA saw a significant jump of 31% YoY to ₹75.09 crore, with an EBITDA margin of 34%. Profit After Tax (PAT) surged by 128% YoY to ₹48.70 crore.
For the full financial year FY26, consolidated revenue grew by 21% YoY to ₹829.04 crore, and Reported EBITDA increased by 38% YoY to ₹262.04 crore. PAT for FY26 rose by 81% YoY to ₹162.85 crore.
The standalone results for Thyrocare Technologies Limited (TTL) also showed strong growth. Revenue from operations increased by 21% YoY to ₹210.67 crore in Q4FY26, and Reported EBITDA grew by 31% YoY to ₹72.63 crore. Standalone PAT jumped by an impressive 101% YoY to ₹43.58 crore for the quarter.
Operational highlights include a 15% YoY growth in quarterly active franchisees to approximately 10,800 and a 29% YoY increase in tests conducted to 5.1 million for Q4FY26. For the full year FY26, tests conducted grew by 23% YoY to 209.6 million.
The company is focusing on deepening its reach in India, strengthening its franchise network, expanding partnerships, and growing its presence in Tanzania. Key strategic initiatives include onboarding Madhuri Dixit as a brand ambassador and receiving national awards.
What to do with a filing like this
Thyrocare Technologies Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Thyrocare Technologies Limited. Read the original for the full detail.